Corticotropin Releasing Factor Receptors in breast cancer: Expression and activity in hormone-dependent growth in vitro.
Breast cancer
CRF
Estrogen
In vitro
Stress
Journal
Peptides
ISSN: 1873-5169
Titre abrégé: Peptides
Pays: United States
ID NLM: 8008690
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
17
12
2019
revised:
11
03
2020
accepted:
13
04
2020
pubmed:
26
4
2020
medline:
8
6
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
Corticotropin Releasing Factor (CRF) neuropeptides coordinate the stress response via two distinct membrane receptors (CRF-Rs). We have previously shown expression of both CRF-Rs in human breast cancer tissues. In the present study, we examined in vitro using the MCF-7 cell line model, the regulation of CRF-Rs expression and their signaling in hormone-dependent breast cancer growth. Our findings show that similarly to breast cancer biopsies, the predominant receptor type expressed in the cell line is CRF-R2α. The transcription of CRF-R1 and CRF-R2 is up and down-regulated respectively by exposure to estradiol (E2); however this effect seems not to be exerted at the level of promoter gene methylation, although in human breast cancer specimens, CRF-R1 methylation was found to be positively associated with the presence of steroid hormone receptors. Finally, we showed that specific activation of CRF-R2 increased the migration of MCF-7 cells and potentiated an estrogen-inducing effect. Our data support an involvement of CRF-R signaling in breast cancer pathophysiology via a regulatory steroid-hormone interplay.
Identifiants
pubmed: 32333998
pii: S0196-9781(20)30065-6
doi: 10.1016/j.peptides.2020.170316
pii:
doi:
Substances chimiques
Receptors, Corticotropin-Releasing Hormone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170316Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.